| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5582017 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 34 Pages |
Abstract
The use of rituximab with anthracycline-based chemotherapy significantly improved the survival of patients with FL3 and should be considered the benchmark by which other therapies for FL3 are evaluated in the future.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Ji Yuan, Timothy C. Greiner, Kai Fu, Lynette M. Smith, Patricia Aoun, Wing C. Chan, Philip J. Bierman, Robert G. Bociek, Julie M. Vose, James O. Armitage, Dennis D. Weisenburger,